Navigation Links
NuVasive Announces Acquisition of Cervical Total Disc Replacement Device
Date:4/22/2009

and and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness(R).

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties, relative to the proposed acquisition, include, but are not limited to: the risk that the parties may not consummate the transaction in the expected timeframe or that intervening factors may cause the parties to alter the terms (financial or otherwise)of the transaction; the risk that NuVasive may not be able to achieve expected synergies and strategic benefits from the technology owned by the acquired company; and the risk that NuVasive will not be able to successfully integrate the operations of the acquired company. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that the Company's financial projections may prove incorrect because of unexpected difficulty in generating sales or achieving anticipated profitability; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. NuVasive Announces Conference Call and Webcast of First Quarter 2009 Results
2. NuVasive to Present at Cowen and Company 29th Annual Healthcare Conference
3. NuVasive to Present at Barclays Capital Global Healthcare Conference
4. NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results
5. NuVasive Announces Web Cast and Conference Call of Fourth Quarter 2008 Results
6. NuVasive to Present at Canaccord Adams Musculoskeletal Conference
7. NuVasive to Present at ROTH 21st Annual OC Growth Stock Conference
8. NuVasive Announces Preliminary Unaudited Full Year 2008 Financial Results
9. NuVasive to Present at 27th Annual J.P. Morgan Healthcare Conference
10. NuVasive to Present at 20th Annual Piper Jaffray Health Care Conference
11. NuVasive Announces Patent Infringement Complaint Brought by Medtronic Sofamor Danek
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... A Xarelto lawsuit webpage has been launched ... with the most current information regarding serious internal bleeding ... as well as the growing number of Xarelto ... The law firm is now offering free legal evaluations ... bleeding and related complications while using Xarelto, including:, ...
(Date:7/13/2014)... 2014 According to The Peripheral Neuropathy ... comprehensive program that teaches people how to deal with ... without medications. This program also provides people with safe ... neuropathy , including numbness, prickling, burning, and intense stabbing ... this home treatment program can help people eliminate some ...
(Date:7/12/2014)... 2014 Recently, iFitDress.com, one of the world’s ... red evening gowns . What’s more, all these hot ... , The company’s senior spokesman states, “We are proud to ... website is an enjoyable shopping experience. In addition to the ... store, low prices do not always mean bad quality. All ...
(Date:7/12/2014)... report, "Phthalic Anhydride and Derivatives (Plasticizers, Unsaturated Polyester Resins, ... Trends & Forecast to 2018," defines and segments phthalic ... and value. The report also estimates the demand and ... anhydride is projected to grow from an estimated $6,130.55 ... a CAGR of 5.24% from 2013 to 2018. , ...
(Date:7/12/2014)... July 12, 2014 The Security Analytics ... 2013 to $3,376.6 million by 2019, at an expected ... 2019. The challenges to counter the increasing number of ... of outdated cyber defense systems in organizations are enormous. ... and remodeling their existing architecture to develop better and ...
Breaking Medicine News(10 mins):Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3Health News:Discounted Red Evening Gown Announced by iFitDress.com 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4
... Stiefel Laboratories, Inc.,("Stiefel Laboratories"), the world,s ... today that the waiting,period under the Hart-Scott-Rodino ... Act") has expired, for its proposed acquisition ... BTRX )., As previously announced, Stiefel ...
... of Adelaide have developed a novel approach to treating ... fewer side effects. , Professor Wayne Tilley and Dr ... Research Laboratories have discovered that by using existing prostate ... doses, they can expect to generate better results for ...
... smoking spouse quits , , TUESDAY, July 29 (HealthDay News) -- ... risk for experiencing a stroke, a new study suggests. , ... who still smoke carry an even greater risk for stroke. ... bear any higher risk for stroke than those married to ...
... Southern Home Medical,Equipment, Inc. (OTC: SHOM) announced today ... solid growth. Industry statistics,suggest a very favorable market ... from the U.S. Bureau of Labor Statistics published ... one million new and,replacement nurses will be needed ...
... for Excellence Issue Brief, WASHINGTON, July 29 ... has issued its second issue brief on retiree,health ... Estimates,of Liabilities. The brief, which was written by ... and entrepreneurship in the,College of Management, North Carolina ...
... single women identify any gaps in coverage or inadequate protection ... ... 2008 -- http://www.combinedinsurance.com/ [Combined Insurance], a leading provider ... 27-August 2, 2008, sponsored by SWWAN® (Single Working Women,s Affiliate ...
Cached Medicine News:Health News:Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc. 2Health News:Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc. 3Health News:Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc. 4Health News:New treatment for advanced prostate cancer 2Health News:Secondhand Smoke Raises Stroke Risk for Spouses 2Health News:Secondhand Smoke Raises Stroke Risk for Spouses 3Health News:Southern Home Medical's Encore Medical Staffing Division Poised to Benefit from Major Growth in Nursing Industry 2Health News:Financing Retiree Health Care: Assessing GASB 45 Estimates of Liabilities 2Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 2Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 3Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 4Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 5
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced ... older adults suffering from the severe cold weather that has ... committed to helping those in need; so to support these ... contributions up to $250,000, which could mean up to $500,000 ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... a leading Clinical Research Organization, announces it is ... World (ECDW), 13-14 May 2009, in London, UK. ... and most highly regarded early development congress. Experts ... be available to discuss PRA,s capabilities at ECDW. ...
... 11 Arno Therapeutics, Inc., a clinical-stage biopharmaceutical ... the U.S. Food and Drug Administration ("FDA") accepted ... the use of AR-12, a potentially first-in-class, orally ... and induces the endoplasmic reticulum stress pathway. ...
Cached Medicine Technology:PRA International: Participating Sponsor for Exploratory Clinical Development World in London 2FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway 2FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: